Sl. Tseng et al., ALLELIC LOSS AT BRCA1, BRCA2, AND ADJACENT LOCI IN RELATION TO TP53 ABNORMALITY IN BREAST-CANCER, Genes, chromosomes & cancer, 20(4), 1997, pp. 377-382
Cells with abnormal TP53 lose cell cycle checkpoints, resulting in gen
omic instability and neoplastic transformation. However, the evidence
linking the tumor-specific targets of genomic alteration to an abnorma
l TP53 is limited. The present study tested the hypothesis that TP53 a
bnormalities are correlated with an increased frequency of deletion of
breast cancer susceptibility loci (17q and 13q) in breast carcinomas.
Tumors from 90 patients were examined for TP53 abnormality and loss o
f heterozygosity (LOH) at 11 loci on 17q (17q11.2-21) and 13q (13q12-1
4), including the loci for BRCA1 and BRCA2. A higher frequency of LOH
was consistently found at 17q or 13q loci in tumors with an abnormal T
P53. The increased LOH in relation to TP53 abnormality was statistical
ly significant at the BRCA1, D17S588, and D13S267 loci (P < 0.05) but
not at the locus for BRCA2 (P = 0.64). These observations imply a poss
ible link between an abnormal TP53 and specific genomic deletions of b
reast cancer susceptibility loci, which may provide clues to the role
of TP53 during breast tumorigenesis. (C) 1997 Wiley-Liss, Inc.